A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF 6523 After Single or Multiple Ascending Doses in Healthy Subjects, Followed by a Placebo Controlled Repeated Dose 2-way Crossover in COPD Subjects
Latest Information Update: 27 Jan 2023
At a glance
- Drugs CHF 6523 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Acronyms CHF6523
- Sponsors Chiesi Farmaceutici
Most Recent Events
- 23 Jan 2023 Status changed from recruiting to completed.
- 28 Oct 2022 Planned End Date changed from 30 Jul 2022 to 30 Dec 2022.
- 28 Oct 2022 Planned primary completion date changed from 30 Jul 2022 to 15 Dec 2022.